Resolución 8430 de 1993: Colombia’s Research Ethics and Risk-Classification Rules

Every research ethics committee (Comité de Ética en Investigación, or CEI) operating in Colombia cites the same foundational instrument: Resolución 8430 de 1993, issued by the then-Ministerio de Salud on 4 October 1993, “por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud” — the norms that establish the scientific, technical and administrative rules for health research. It is the regulation that defines Colombia’s three-tier research-risk classification and the informed-consent rules built on top of it, and it is still, as of this writing, the governing text for both.

It is easy to conflate this resolution with INVIMA’s clinical-trial approval pathway, but they are not the same instrument. Resolución 8430 is the general research-ethics framework that applies to all health research involving human subjects in Colombia, drug trials included. INVIMA’s own approval authority for medicinal-product trials — GCP certification, the “no objection,” ongoing inspection — comes from a separate, later instrument, Resolución 2378 de 2008, which sits on top of 8430 for pharmacological research specifically rather than replacing it. See CASRAI’s INVIMA Colombia Clinical Trial Approval Pathway guide for that regulatory-approval track; this page covers the ethics-and-risk framework underneath it.

What Resolución 8430 de 1993 actually covers

Article 2 requires every institution conducting research on human subjects to maintain its own Comité de Ética en Investigación, responsible for resolving all matters related to the research. Article 3 requires each institution to build an internal procedures manual to support applying the norms. The substantive rules a CEI actually applies day to day sit in Título II, “De la Investigación en Seres Humanos” — risk classification (Article 11) and informed consent (Articles 14–16) — which is the material this page covers in detail. Separate titles (III and IV) govern pharmacological research and community research specifically; those are the titles Resolución 2378/INVIMA layers additional GCP requirements onto.

The three risk categories under Article 11 — with the actual examples the resolution gives

Article 11 classifies every study into exactly one of three categories. The resolution doesn’t just name them — it lists concrete study types for each, which is what a CEI actually uses to classify a protocol:

Investigación sin riesgo (no risk)

Studies using retrospective documentary research techniques and methods, and any study involving no intentional intervention or modification of the biological, physiological, psychological or social variables of participants. The resolution’s own examples: medical-record review, interviews, questionnaires, and similar methods that do not identify the subject or address sensitive aspects of their conduct.

Investigación con riesgo mínimo (minimal risk)

Prospective studies that record data through common diagnostic or routine-treatment procedures. Article 11(b) lists these examples specifically:

• Weighing the subject; electrocardiograms; hearing-acuity tests; thermography
• Collection of excreta and external secretions; obtaining placenta at delivery; collecting amniotic fluid when membranes rupture; obtaining saliva
• Deciduous and permanent teeth extracted for therapeutic reasons; dental plaque and calculus removed by non-invasive prophylactic procedures; hair and nail trimming without causing disfigurement
• Venous blood draws in healthy adults, capped at twice a week and 450 mL over two months — except during pregnancy
• Moderate exercise in healthy volunteers; psychological tests on groups or individuals where the subject’s conduct is not manipulated
• Research with commonly-used medicines that have a wide therapeutic margin and are already registered with the Ministry (or its delegated authority), used at established doses, indications and routes of administration — provided they are not the medicines defined under the resolution’s own Article 55 (the pharmacological-research title’s stricter category)

Investigaciones con riesgo mayor que el mínimo (greater than minimal risk)

Studies where the probability of affecting the subject is significant. Article 11(c)’s examples: radiological and microwave studies; studies involving the medicines and modalities defined under Títulos III and IV; trials of new devices; studies involving surgical procedures; blood draws exceeding 2% of circulating volume in neonates; amniocentesis and other invasive techniques or major procedures; studies using random assignment to therapeutic regimens; and placebo-controlled studies.

For the underlying comparison logic a CEI applies between the last two tiers, see CASRAI’s Minimal Risk vs. Greater Than Minimal Risk in Human Subjects Research comparison.

Informed consent: what it must contain, and when it can be waived

Article 14 defines Consentimiento Informado as the written agreement by which the research subject — or their legal representative — authorizes participation with full knowledge of the procedures, benefits and risks involved, freely and without coercion. See also CASRAI’s ICF (Informed Consent Form) entry for the general concept.

What the consent document must disclose (Article 15)

Explained fully and clearly to the subject or their legal representative, in terms they can understand:

• The justification and objectives of the research
• The procedures to be used and their purpose, identifying which are experimental
• The expected discomforts or risks, and the potential benefits
• Any alternative procedures that could be advantageous to the subject
• A guarantee of answers to any question about procedures, risks, benefits or related matters
• Freedom to withdraw consent at any time without prejudice to continued care
• Assurance of confidentiality and non-identification
• A commitment to share updated study information, even if it could affect willingness to continue
• Availability of medical treatment and legally-owed compensation for research-caused harm
• How any additional costs are covered

What makes consent valid (Article 16)

• Drafted by the principal investigator, using the Article 15 content
• Reviewed by the institution’s Comité de Ética en Investigación
• Names, addresses and relationship-to-subject of two witnesses
• Signed by both witnesses and the subject (or legal representative) — a subject who cannot write uses a fingerprint, with another person signing on their behalf at their designation
• Executed in duplicate, with one copy retained by the subject or representative

The waiver: minimal-risk and no-risk research (Article 16, Parágrafo Primero)

This is the provision that answers the “can consent be skipped” question directly. For riesgo mínimo research, the institution’s CEI may — for justified reasons — authorize consent to be obtained without a signed written document. For sin riesgo research, the CEI may go further and dispense with obtaining consent altogether. Both are committee decisions, not defaults: nothing in the resolution waives consent automatically by category, and the greater-than-minimal-risk tier has no waiver provision at all.

Special situations (Parágrafos Segundo–Quinto)

• Dependency or subordination between subject and investigator: consent must be obtained by another team or institution member fully independent of that relationship
• Mental-capacity determination: the principal investigator must involve a neurologist, psychiatrist or psychologist to assess understanding and reasoning, per parameters the CEI approves
• Capacity that may have changed over time: consent (subject’s or representative’s) must be endorsed by a recognized specialist in the relevant field, plus an independent observer with no relation to the research
• Institutionalized psychiatric patients: prior approval from the authority responsible for the case is required in addition to the standard consent process

The Comité de Ética en Investigación: what 8430 requires — and what it leaves open

Resolución 8430 establishes that a CEI must exist (Article 2) and gives it real, binding functions throughout the text: reviewing and approving informed-consent documents (Article 16(b)), approving the mental-capacity assessment parameters (Article 16, Parágrafo Tercero), and — for pharmacological research under Título III — studying and approving research projects against a defined document checklist (Article 50).

What the resolution does not do: it does not itself prescribe a minimum committee size, professional-background mix, quorum, term length, or a national registration procedure for a CEI. Those operational details, where they exist, come from other instruments layered on top — for institutions conducting drug research under GCP, from Resolución 2378 de 2008’s technical annex (see CASRAI’s INVIMA Colombia Clinical Trial Approval Pathway guide). CASRAI could not verify a single, general-purpose CEI composition or registration requirement that applies to every Colombian research institution regardless of research type, and does not assert one here — if your institution’s research falls outside the GCP/INVIMA track, confirm current committee-composition expectations directly with Minsalud rather than assuming a fixed formula.

What still applies after later decrees

As of this writing, Título I and Título II of Resolución 8430 de 1993 — meaning the general provisions, the Article 11 risk classification and the Article 14–16 informed-consent rules covered above — remain in force. No later instrument has repealed or replaced them.

Two things are worth distinguishing clearly:

• Resolución 2378 de 2008 is already in force and already changes the picture for one slice of research: it requires INVIMA GCP certification and an institutional ethics committee meeting its own technical annex for institutions conducting drug research in human subjects. It supplements Título III/IV of 8430 for that specific research category; it does not touch Título II’s general risk-classification or consent rules that apply to non-drug health research.
• A draft resolution is not yet in force. Colombia’s Ministerio de Salud y Protección Social published a proyecto de resolución for public consultation (reported publicly around February 2026) that would update requirements for informed consent, risk assessment, data protection, ethics-committee composition, insurance/compensation and study registration. Its own text is explicit about scope: Article 51 of the draft states it would repeal precisely Título I and Título II of Resolución 8430 de 1993 — the exact provisions this page describes — once adopted. The draft copy CASRAI reviewed carries no assigned resolution number and no publication date (“RESOLUCIÓN NÚMERO ___ DE 2026”), which is itself evidence it had not been formally issued as of that draft.

What CASRAI could not verify and does not assert: whether the public-consultation period has since closed, whether the draft has been revised, or whether it has been formally adopted between the February 2026 reporting available and this writing. Confirm current status directly against Minsalud’s own Normatividad publications before relying on this page for a live protocol submission — if the resolution has since been issued, the risk-classification and consent provisions above would need to be re-checked against its final text, not this one.

Frequently asked questions

Does Resolución 8430 apply to drug trials, or only INVIMA-regulated ones?

It applies to all human-subjects health research in Colombia, drug trials included — Título II’s risk classification and consent rules are the general layer. Drug trials additionally have to clear INVIMA’s approval process under Resolución 2378 de 2008, which is a separate, additive requirement, not a replacement.

Can informed consent be skipped entirely for “sin riesgo” research?

Only by decision of the institution’s CEI, under Article 16’s Parágrafo Primero — it is a committee authorization, not an automatic exemption by category.

What’s the maximum blood volume allowed under the “riesgo mínimo” category?

Article 11(b) caps venous blood draws in healthy adults at twice weekly, with a maximum of 450 mL over two months, except during pregnancy.

Is Resolución 8430 de 1993 still in force in 2026?

Yes, as of this writing. A Minsalud draft resolution proposes to repeal Título I and Título II specifically, but it remained an unnumbered, undated draft in public consultation the last time CASRAI could confirm its status.

Does 8430 set a required number of CEI members?

No — CASRAI could not find a general committee-composition or quorum requirement in the resolution’s own text. Composition detail exists for drug-research institutions under Resolución 2378 de 2008’s technical annex; outside that track, confirm current expectations with Minsalud directly.

Related CASRAI resources

For the separate drug-trial regulatory-approval track this resolution feeds into, see INVIMA Colombia Clinical Trial Approval Pathway. For the broader GCP framework Colombian drug research aligns to, see ICH GCP (Good Clinical Practice) and Good Clinical Practice (GCP) Certification. For the general risk-tier comparison used across jurisdictions, see Minimal Risk vs. Greater Than Minimal Risk in Human Subjects Research. For the consent-document concept itself, see ICF (Informed Consent Form). For Colombia’s separate research-integrity oversight structure, see Colombia’s Research Integrity Oversight: Minciencias and the National Bioethics Council. For the wider human-subjects-protection knowledge base, see the Integrity & Compliance pillar.